Active Biotech AB Interim report January-June 2014
August 07 2014 - 2:30AM
Laquinimod
-
On May 23, the European Medicines Agency's
Committee for Medicinal Products for Human Use (CHMP) reaffirmed
its negative opinion on the market application for laquinimod
(Nerventra®)
-
CHMP confirmed that the risks observed in animal
studies do not prevent a registration for treatment in humans
-
The ongoing US pivotal clinical study CONCERTO
is continuing according to plan. The results are expected in
2016
Tasquinimod
ANYARA
Paquinimod (57-57)
ISI
Financial
summary
MSEK |
April - June |
|
January - June |
|
Full Year |
|
2014 |
2013 |
|
2014 |
2013 |
|
2013 |
|
|
|
|
|
|
|
|
Net sales |
2.7 |
2.5 |
|
4.9 |
5.0 |
|
116.0 |
Operating loss |
-57.9 |
-79.5 |
|
-117.2 |
-156.5 |
|
-209.0 |
Loss for the period |
-57.7 |
-81.2 |
|
-117.9 |
-159.2 |
|
-212.1 |
Loss per share (SEK) |
-0.77 |
-1.08 |
|
-1.57 |
-2.18 |
|
-2.87 |
For further information,
please contact:
Tomas Leanderson, President and
CEO
Tel: +46 (0)46 19 20 95
Hans Kolam, CFO
Tel: +46 (0)46 19 20 44 |
Active Biotech AB
(Corp. Reg. No. 556223-9227)
Box 724, SE-220 07 Lund
Tel: +46 (0)46 19 20 00
Fax: +46 (0)46 19 11 00
The report is also available at
www.activebiotech.com |
|
Active Biotech AB Interim report
January-June 2014
This
announcement is distributed by NASDAQ OMX Corporate Solutions on
behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: Active Biotech via Globenewswire
HUG#1846988
Actividentity Corp (MM) (NASDAQ:ACTI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Actividentity Corp (MM) (NASDAQ:ACTI)
Historical Stock Chart
From Apr 2023 to Apr 2024